Q1 FY2026 · ended Mar 31, 2026 · Revenue $1.44M, -77.6% YoY · Filed May 14, 2026
Sangamo Therapeutics, Inc. (SGMOQ) files with the SEC under industry code 2836, Biological Products, (No Diagnostic Substances). In Q1 of fiscal 2026, the quarter ended Mar 31, 2026, it reported revenue of $1.4 million and a net loss of $31.0 million. Free cash flow was -$19.3 million. As of Mar 31, 2026 it held $27.6 million in cash and investments and $19.3 million in total debt.
Company profile
- Industry
- Biological Products, (No Diagnostic Substances) (SIC 2836)
- Listed as
- SGMOQ (OTC)
- Fiscal year ends
- December 31
- Incorporated in
- DE
- Headquarters
- Richmond, CA
- SEC filer status
- Non-accelerated filer, Smaller reporting company
- SEC CIK
- 1001233
- Former names
- SANGAMO BIOSCIENCES INC (until Jan 6, 2017)
Other Biological Products, (No Diagnostic Substances) companies
- Amgen Inc AMGN
- Gilead Sciences, Inc. GILD
- Moderna, Inc. MRNA
- Argenx SE ARGX
- Revolution Medicines, Inc. RVMD
- Biogen Inc. BIIB
- BioNTech SE BNTX
- Exelixis, Inc. EXEL
All 182 Biological Products, (No Diagnostic Substances) companies
Key figures
Fiscal-year totals from the annual reports; switch to Annual for the full-year view. Balance sheet lines are as of each year end.
| Line | Q1 FY2026 Mar 31, 2026 |
Q4 FY2025 Dec 31, 2025 |
Q3 FY2025 Sep 30, 2025 |
Q2 FY2025 Jun 30, 2025 |
Q1 FY2025 Mar 31, 2025 |
|---|---|---|---|---|---|
| Revenue | $1.4M | $14.2M | $581,000 | $18.3M | $6.4M |
| Operating income | -$31.9M | -$38.2M | -$35.6M | -$17.9M | -$29.6M |
| Net income | -$31.0M | -$37.4M | -$34.9M | -$20.0M | -$30.6M |
| Diluted EPS | -$0.08 | -$0.11 | -$0.11 | -$0.08 | -$0.14 |
| Operating cash flow | -$19.3M | -$24.4M | -$28.5M | -$18.2M | -$26.1M |
| Free cash flow | -$19.3M | -$24.4M | -$28.6M | -$18.2M | — |
| Total assets | $60.0M | $59.7M | $88.6M | $97.6M | $86.2M |
| Total liabilities | $78.9M | $74.0M | $82.4M | $78.0M | $81.3M |
| Stockholders' equity | -$19.0M | -$14.3M | $6.2M | $19.6M | $4.9M |
| Cash and investments | $27.6M | $20.9M | $29.6M | $38.3M | $25.2M |
| Total debt | $19.3M | $26.8M | $25.4M | $23.5M | $24.9M |
Recent SEC filings
| Form | Description | Filed | Period |
|---|---|---|---|
| 8-K |
Current report
Regulation FD disclosure
|
Oct 27, 2026 | Oct 23, 2026 |
| 8-K |
Current report
Regulation FD disclosure
|
Oct 16, 2026 | Oct 14, 2026 |
| 8-K |
Current report
Bankruptcy, Acquisition or sale of assets
|
Sep 21, 2026 | Sep 17, 2026 |
| 8-K |
Current report
Bankruptcy, Acquisition or sale of assets, Regulation FD disclosure
|
Sep 8, 2026 | Sep 2, 2026 |
| 8-K |
Current report
Material agreement, Bankruptcy
|
Aug 28, 2026 | Aug 25, 2026 |
| 8-K |
Current report
Other events
|
Aug 13, 2026 | Aug 12, 2026 |
All 1000 Sangamo Therapeutics, Inc. SEC filings
Source: SEC EDGAR filings. This is company-reported data, not investment advice.